Skip to main content
main-content

08-12-2019 | Haematology | Video

ASH 2019 | Distinct CLL cell populations provide rationale for combining drugs to minimize residual disease

Yue Lynn Wang gives an overview of her team’s chronic lymphocytic leukaemia proliferation model, which has demonstrated the benefits of combining ibrutinib and venetoclax (5:11).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.